| Literature DB >> 28404909 |
Ming-Yu Lien1,2, Chiao-Wen Lin3,4, Hsiao-Chi Tsai1, Yng-Tay Chen5, Ming-Hsui Tsai6, Chun-Hung Hua7, Shun-Fa Yang8,9, Chih-Hsin Tang1,10.
Abstract
In Taiwan, oral cancer has causally been associated with environmental carcinogens. CCL4 (C-C chemokine ligand 4), a macrophage inflammatory protein with a key role in inflammation and immune-regulation, was implicated in carcinogenesis by facilitating instability in the tumor environment. The purpose of this study was to identify gene polymorphisms of CCL4 specific to patients with oral squamous cell carcinoma (OSCC) susceptibility and clinicopathological characteristics. A total of 2,053 participants, including 1192 healthy people and 861 patients with oral cancer, were recruited for this study. Three single-nucleotide polymorphisms (SNPs) of the CCL4 gene were analyzed by a real-time PCR. We found that the T/T homozygotes of CCL4 rs1634507 G/T polymorphism and the GG haplotype of 2 CCL4 SNPs (rs1634507 and rs10491121) combined were associated with oral-cancer susceptibility. In addition, TA haplotype significantly decreased the risks for oral cancer by 0.118 fold. Among 1420 smokers, CCL4 polymorphisms carriers with the betel-nut chewing habit had a 15.476-20.247-fold greater risk of having oral cancer compared to CCL4 wild-type (WT) carriers without the betel-nut chewing habit. Finally, patients with oral cancer who had A/G heterozygotes of CCL4 rs10491121 A/G polymorphism showed a lower risk for an advanced tumor size (> T2) (p=0.046), compared to those patients with AA homozygotes. Our results suggest that the CCL4 rs1634507 SNP have potential predictive significance in oral carcinogenesis. Gene-environment interactions of CCL4 polymorphisms might influence oral-cancer susceptibility. CCL4 rs10491121 may be a factor to predict the tumor size in OSCC patients.Entities:
Keywords: CCL4; oral cancer; single-nucleotide polymorphism
Mesh:
Substances:
Year: 2017 PMID: 28404909 PMCID: PMC5458219 DOI: 10.18632/oncotarget.15615
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Demographical characteristics in 1192 controls and 861 male patients with oral cancer
| Variable | Controls | Patients | |
|---|---|---|---|
| Age (yrs) | Mean ± S.D. | Mean ± S.D. | |
| 53.90 ± 10.01 | 54.92 ± 11.04 | ||
| Betel quid chewing | |||
| No | 993 (83.3%) | 170 (19.7%) | |
| Yes | 199 (16.7%) | 691 (80.3%) | |
| Cigarette smoking | |||
| No | 558 (46.8%) | 86 (10.0%) | |
| Yes | 634 (53.2%) | 775 (90.0%) | |
| Alcohol drinking | |||
| No | 956 (80.2%) | 390 (45.3%) | |
| Yes | 236 (19.8%) | 471 (54.7%) | |
| Stage | |||
| I+II | 427 (49.6%) | ||
| III+IV | 434 (50.4%) | ||
| Tumor T status | |||
| T1+T2 | 495 (57.5%) | ||
| T3+T4 | 366 (42.5%) | ||
| Lymph node status | |||
| N0 | 582 (67.6%) | ||
| N1+N2+N3 | 279 (32.4%) | ||
| Metastasis | |||
| M0 | 852 (99.0%) | ||
| M1 | 9 (1.0%) | ||
| Cell differentiation | |||
| Well differentiated | 124 (14.4%) | ||
| Moderately or poorly differentiated | 737 (85.6%) |
Mann-Whitney U test or Fisher's exact test was used between healthy controls and patients with oral cancer. * p value < 0.05 as statistically significant.
Odds ratio (OR) and 95% confidence interval (CI) of oral cancer associated with CCL4 genotypic frequencies
| Variable | Controls n=1192(%) | Patients n=861 (%) | OR (95% CI) | |
|---|---|---|---|---|
| GG | 585 (49.1%) | 391 (45.4%) | 1.000 (reference) | |
| GT | 518 (43.5%) | 382 (44.4%) | 1.103 (0.918-1.326) | |
| TT | 89 (7.4%) | 88 (10.2%) | 1.479 (1.073-2.040) | |
| GT+TT | 607 (50.9%) | 470 (54.6%) | 1.158 (0.972-1.381) | |
| G allele | 1688 (70.8%) | 1164 (67.6%) | 1.000 (reference) | |
| T allele | 696 (29.2%) | 558 (32.4%) | 1.163 (1.017-1.329) | |
| AA | 307 (25.8%) | 214 (24.9%) | 1.000 (reference) | |
| AG | 592 (49.7%) | 428 (49.7%) | 1.037 (0.837-1.285) | |
| GG | 293 (24.5%) | 219 (25.4%) | 1.072 (0.837-1.373) | |
| AG+GG | 885 (74.2%) | 647 (75.1%) | 1.049 (0.857-1.283) | |
| A allele | 1206 (50.6%) | 856 (49.7%) | 1.000 (reference) | |
| G allele | 1178 (49.1%) | 866 (50.3%) | 1.036 (0.915-1.172) | |
| AA | 541 (45.4%) | 391 (45.4%) | 1.000 (reference) | |
| AT | 538 (45.1%) | 383 (44.5%) | 0.985 (0.819-1.185) | |
| TT | 113 (9.5%) | 87 (10.1%) | 1.066 (0.783-1.450) | |
| AT+TT | 651 (54.6%) | 470 (54.6%) | 0.999 (0.838-1.191) | |
| A allele | 1620 (68.0%) | 1165 (67.7%) | 1.000 (reference) | |
| T allele | 764 (32.0%) | 557 (32.3%) | 1.014 (0.888-1.158) |
The odds ratio (OR) with their 95% confidence intervals were estimated bylogistic regression models. * p value < 0.05 as statistically significant.
Associations of the combined effect of CCL4 gene polymorphisms and betel nut chewing with the susceptibility to oral cancer among 1420 smokers
| Variable | Controls n=634 (%) | Patients n=775 (%) | OR (95% CI) | AOR (95% CI) |
|---|---|---|---|---|
| GG genotype & non-betel nut chewing | 208 (32.8%) | 47 (06.1%) | 1.000 | 1.000 (reference) |
| GT or TT genotype or betel nut chewing | 336 (53.0%) | 375 (48.4%) | ||
| GT or TT genotype with betel nut chewing | 90 (14.2%) | 353 (45.5%) | ||
| AA genotype & non-betel nut chewing | 106 (16.7%) | 20 (02.6%) | 1.000 | 1.000 (reference) |
| AG or GG genotype or betel nut chewing | 396 (62.5%) | 265 (34.2%) | ||
| AG or GG genotype with betel nut chewing | 132 (20.8%) | 490 (63.2%) | ||
| AA genotype & non-betel nut chewing | 201 (31.7%) | 45 (5.8%) | 1.000 | 1.000 (reference) |
| AT or TT genotype or betel nut chewing | 332 (52.4%) | 381 (49.2%) | ||
| AT or TT genotype with betel nut chewing | 101 (15.9%) | 349 (45.0%) |
The adjusted odds ratio (AOR) with their 95% confidence intervals was estimated by multiple logistic regression models after controlling for age.
Odds ratio (OR) and 95% confidence intervals (CI) of clinical status associated with genotypic frequencies of CCL4 rs10491121 in 861 male oral cancer patients
| Variable | AOR (95% CI) | |||
|---|---|---|---|---|
| Clinical Stage | ||||
| Stage I+IIn=427 (%) | Stage III+IVn=434 (%) | |||
| AA | 100 (23.4%) | 114 (26.3%) | 1.00 | |
| AG | 217 (50.8%) | 211 (48.6%) | 1.186 (0.853-1.649) | |
| GG | 110 (25.8%) | 109 (25.1%) | 1.161 (0.796-1.694) | |
| Tumor size | ||||
| ≦ T2n=495 (%) | > T2n=366 (%) | |||
| AA | 111 (22.4%) | 103 (28.1%) | 1.00 | |
| AG | 258 (52.1%) | 170 (46.5%) | ||
| GG | 126 (25.5%) | 93 (25.4%) | 0.799 (0.547-1.168) | |
| Lymph node metastasis | ||||
| Non=852 (%) | Yesn=9 (%) | |||
| AA | 212 (24.9%) | 2 (22.2%) | 1.00 | |
| AG | 423 (49.7%) | 5 (55.6%) | 1.254 (0.241-6.527) | |
| GG | 217 (25.4%) | 2 (22.2%) | 0.978 (0.136-7.010) | |
| Cell differentiated grade | ||||
| ≦Grade In=124 (%) | >Grade In=737 (%) | |||
| AA | 36 (29.0%) | 178 (24.2%) | 1.00 | |
| AG | 50 (40.3%) | 378 (51.3%) | 0.650 (0.490-1.035) | |
| GG | 38 (30.7%) | 181(24.6%) | 1.033 (0.626-1.705) | |
Cell differentiate grade: grade I: well differentiated; grade II: moderately differentiated; grade III: poorly differentiated.
The adjusted odds ratio (AOR) with their 95% confidence intervals were estimated by multiple logistic regression models after controlling for age.* p value < 0.05 as statistically significant.
Odds ratio (OR) and 95% confidence interval (CI) of oral cancer associated with CCL4 rs1634507/rs10491121 haplotype frequencies
| Haplotype block | Controls n = 2384 | Patients n = 1722 | AOR (95% C.I.) |
|---|---|---|---|
| Block 1: rs1634507/rs10491121 | |||
| G/A | 1165 (48.9%) | 875 (50.8%) | 1.000 (reference) |
| T/G | 701 (29.4%) | 531 (30.8%) | 0.999 (0.866-1.153) |
| G/G | 515 (21.6%) | 297 (17.3%) | |
| T/A | 3 (0.1%) | 19 (1.1%) |
The adjusted odds ratio (AOR) with their 95% confidence intervals was estimated by multiple logistic regression models after controlling for age. * p value < 0.05 as statistically significant.
Figure 1Linkage disequilibrium (LD) map for single nucleotide polymorphisms in the CCL4 gene
There are 2053 participants, including 1192 healthy people and 861 patients with oral cancer, in this study. Block is pairwise D’ plots and haplotype blocks obtained from HAPLOVIEW.